Maximum SCRs were generally larger post rTMS.
Maximum proteinuria values of the remaining 2,497 patients and maximum sCr values of the 396 patients, whose TBSA > 30%, were recorded, in which maximum proteinuria was defined as the maximum value before AKI incidence for patients with AKI.
Increases in SCr were generally <0.06 mg/dL for this group of patients (maximum SCr changes of 0.12 and 0.13 mg/dL for the tofacitinib → placebo and placebo → placebo groups, respectively).
In Table 2 the minimum and maximum Scr obtained from the individual measurements of each pool in the study can be found.
SCRs after booster vaccination (booster SCR) were based on increases in HI antibody titers from the pre-booster titer measured at the booster time-point.
For example, the maximum mean SCr concentration was 826 μmol/l, and the highest SCr levels in 14 of the 16 patients in this group were higher than the level indicative of uremia.
To estimate the effect of the variation in Scr determinations on the eGFR, we calculated eGFR values corresponding with the minimum and maximum determined Scr values of each pool for some specific patient cases.
When diagnosing the AKI, 102 achieved RIFLE maximum by sCr criteria, 19 by urine criteria and 31 by both criteria.
In the absence of known baseline serum creatinine (sCr) levels, the nadir of sCr after renal recovery was recorded to evaluate baseline renal function.
